Abstract
cis-1,1-Cyclobutanedicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) (NK121) andcis-diammine(glycolato)platinum (254-S), analogues ofcis-diamminedichloroplatinum (II) (CDDP) with reduced nephrotoxicity, are under clinical phase trial in Japan. Since CDDP has been shown to be more cytotoxic under conditions of an elevated temperature, we tested the cytotoxicity and cellular uptake of these analogues at 37° and 43°C using EMT6/KU cells in vitro. The cytotoxicity of CDDP was enhanced at 43°C, and that of NK121 and 254-S was also enhanced, in a dose- and time-dependent manner. The 90% cytotoxic concentration (IC90) of each drug was reduced 2.9-fold for CDDP, 2.5-fold for NK121, and 2.2-fold for 254-S. Cytotoxicity was maximal when the two modalities were used simultaneously for all three drugs. The intracellular platinum concentration was assayed using flameless atomic absorption spectrophotometry. When exposed to IC90 drug concentration at 43°C for 2 h simultaneously, the intracellular platinum concentration increased to 0.095±0.007 μg/107 cells (a 1.9-fold increase) for CDDP, to 0.198±0.012 μg/107 cells (a 1.3-fold increase) for NK121, and to 0.090±0.014 μg/107 cells (a 1.3-fold increase) for 254-S; respectively, as compared with the level measured after drug exposure at 37°C (P<0.05 for all drugs). The elevation in platinum concentration may be one of mechanism related to a synegistic effect of the two treatment modalities. The concomitant use of CDDP analogues and heat shows potential for possible clinical application.
Similar content being viewed by others
References
Alberts DS, Peng YM, Chen HSG, Moon TE, Cetas TC, Hoeschele JD (1980) Therapeutic synergism of hyperthermia-cisplatin in a mouse tumor model. J Natl Cancer Inst 65: 455
Baba H, Siddik ZH, Strebel FR, Jenkins GN, Bull JMC (1989) Increased therapeutic gain of combinedcis-diamminedichloroplatinum(II) and whole body hyperthermia by optimal heat/drug scheduling. Cancer Res 49: 7041
Cohen JD, Robins HI (1987) Hyperthermic enhancement ofcis-diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro. Cancer Res 47: 4335
Connors TA, Cleare MJ, Harrap KR (1979) Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat Rep 63: 1499
Durant JR (1980) Cisplatin: a clinical overview. In: Prestyko AW, Crooke ST, Carner SK (eds) Cisplatin: current status and new developments. Academic Press, New York, p 317
Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K, Miyazaki I (1990) Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65: 65
Fukuoka M, Niitani K, Hasegawa K, Majima H, Hino M, Furuse H., Tsukagoshi S, Fujita H, Ohta K, Furuse K, Kimura I, Katoh H (1989) Phase I study of new platinum compound, NK121. Proc Am Soc Clin Oncol 8: 240
Gerad H, Egorin MJ, Whitacre M, Van Echo DA, Aisner J (1983) Renal failure and platinum pharmacokinetics in three patients treated withcis-diamminedichloroplatinum(II) and whole-body hyperthermia. Cancer Chemother Pharmacol 11: 162
Hahn GM (1979) Potential for therapy of drugs and hyperthermia. Cancer Res 39: 2264
Herman TS, Teicher BA, Cathcart KNS, Kaufmann ME, Lee JB, Lee MH (1988) Effect of hyperthermia oncis-diamminedichloroplatinum(II), (rhodamine123)2[tetrachloroplatinum(II)] in a human squamous cell carcinoma line and acis-diamminedichloroplatinum(II)-resistant subline. Cancer Res 48: 5101
Herman TS, Teicher BA, Chan V, Collins LS, Kaufmann ME, Loh C (1988) Effect of hyperthermia on the action ofcis-diamminedichloroplatinum(II), rhodamine1232[tetrachloroplatinum(II)], rhodamine123, and potassium tetrachloroplatinate in vitro and in vivo. Cancer Res 48: 2335
Herman TS, Jochelson MS, Teicher BA, Scott PJ, Hansen J, Clark JR, Pfeffer MR, Gelwan LE, Molmar-Griffin BJ, Fraser SM, Svennson G, Bornsten BA, Coleman CN (1989) A phase I–II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies. Int J Radiat Oncol Biol Phys 17: 1273
Inuyama Y, Miyake H, Ohta K (1990) Phase II study of 254-S for head and neck cancer. J Cancer Res Clin Oncol 116 [Suppl 1]: 696
Kato T, Noda K, Terashima Y, Hirabayashi K, Nishiyama H (1989) Phase II study of 254-S, a new platinum complex, for gynecological malignancy. Proceedings of the 16th International Congress of Chemotherapy, 16 (June 1989, Jerusalem, Israel) p 823
Knox RJ, Friedlos F, Lydall DA, Roberts J (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence thatcis-diamminedichloroplatinum(II) andcis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46: 1972
Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion. Cancer 61: 232
Kraker AJ, Moore CW, Leopold WR, Takahashi K (1988) Preclinical characterization of the in vitro and in vivo activity of [1,1′-cyclobutanedicarboxylato(2-)-O,O′](2-methyl-1,4-butanediamine-N,N′)Pt] (NK121/CI-973). Proc Am Assoc Cancer Res 29: 1370
Leroy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18: 184
Los G, Sminia P, Wondergem J, Mutasaers PHA, Havemen J, Huinink DB, Smals O, Gonzalez D, McVie JG (1991) Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 27: 472
Matsufuji H, Kuwano H, Kai H, Matsuda H, Sugimachi K (1988) Preoperative hyperthermia combined with radiotherapy and chemotherapy for patients with incompletely resected carcinoma of the esophagus. Cancer 62: 889
Meyn RE, Corry PM, Fletcher SE, Demetriades M (1980) Thermal enhancement of DNA damage in mammalian cells treated withcis-diamminedichloroplatinum(II). Cancer Res 40: 1136
Micetich KC, Barnes D, Erickson LC (1985) A comparative study of the cytotoxicity and DNA-damaging effects ofcis-(diammino)(1,1-cyclobutanedicarboxylato)platinum(II) andcis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res 45: 4043
Ohno S, Siddik ZH, Baba H, Stephens C, Strebel FR, Wondergem J, Khokhar AR, Bull JMC (1991) Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 51: 2994
Rice GC, Hahn GM (1987) Modulation of Adriamycin transport by hyperthermia as measured by fluorescence-activated cell sorting. Cancer Chemother Pharmacol 20: 183
Shiratori O, Kanai H, Uchida N, Takeda Y, Totani T, Sato K (1985) Antitumor activity of 254-S, a platinum complex, in rodents. In: Ishigami J (ed) Recent advances in chemotherapy. University of Tokyo Press, Tokyo, p 635
Sugimachi K, Matsuda H, Ohno S, Fukuda A, Matsuoka H, Mori M, Kuwano H (1988) Long term effects of hyperthermia combined with chemotherapy and irradiation for the treatment of patients with carcinoma of the esophagus. Surg Gynecol Obstet 167: 319
Takahashi K, Kotawa O (1989) NK121. Drugs Future 14: 31
Totani T, Aono K, Adachi Y, Komura M, Shiratori O, Sato K (1987) Bidentate hydroxycarboxylic acid platinum(II) complexes with antitumor activity. Proceedings of the 5th Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, 5, p 744 (June 29–July 2, 1987, Padua, Italy)
Wallner KE, Li GC (1987) Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. Cancer Res 47: 493
Wallner KE, DeGeorge MW, Li GC (1986) Hyperthermic potentiation ofcis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the durg. Cancer Res 46: 6242
Zwelling LA, Kohn KW (1979) Mechanism of action ofcis-dichlorodiammineplatinum(II), Cancer Treat Rep 63: 1439
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takahashi, I., Maehara, Y., Kusumoto, H. et al. Heat enhances the cytotoxicity ofcis-diamminedichloroplatinum(II) and its analoguescis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) andcis-diammine(glycolato)platinum in vitro. Cancer Chemother. Pharmacol. 33, 31–35 (1993). https://doi.org/10.1007/BF00686019
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686019